Protocol No FOCUS in CML v6 F.O.C.U.S. in CML. Real-World Evidence (RWE) in Greece in patients with Chronic Myeloid Leukemia – Chronic Phase (CML-CP) who have already received at least one dose of Imatinib 600 mg following suboptimal response or failure to Imatinib 400 mg Start date 02/11/2026 End date 30/11/2027 Medical condition CML More →
EudraCT / EU CT No 2025-523544-12-00 Protocol No TAK-226-3001 A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions Start date 29/09/2026 Medical condition MDS More →
EudraCT / EU CT No 2025-524793-42 Protocol No 79635322MMY2002 A Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic use of Tocilizumab to Prevent Cytokine Release Syndrome with JNJ-79635322 (Ramantamig) administration in Participants with Relapsed or Refractory Multiple Myeloma Start date 01/09/2026 Medical condition R/R MM More →
EudraCT / EU CT No 2025-522267-15-00 Protocol No MK1045-005 A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) Start date 31/07/2026 Medical condition ALL More →
EudraCT / EU CT No 2025-523117-28 Protocol No DREAMM-15 A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma Start date 24/07/2026 Medical condition RRM More →
Protocol No 79635322MMY3002/TRIlogy-5 A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1-3 prior lines of therapy Start date 17/07/2026 End date End of 2030 Medical condition MM More →
EudraCT / EU CT No 2024-518420-80-00 Protocol No TAK-339-3001 A Multicenter, Randomized, Controlled, Open-Label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3-Directed Bispecific Antibody Therapy Start date 13/07/2026 Medical condition MM More →
EudraCT / EU CT No 2022-501560-17-00 Protocol No MK1026-010 A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) Start date 02/07/2026 Medical condition R/R CLL/SLL More →
EudraCT / EU CT No 2024-516869-36-00 Protocol No EXS73565-001 A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies Start date 17/06/2026 End date Recruiting Medical condition CLL, DLBCL, MCL, MZL, WALDENSTROM, FL More →
EudraCT / EU CT No 2025-521372-62-00 Protocol No 79635322MMY3002 TRIlogy-5 — JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma Start date 31/05/2026 End date 08/12/2032 Medical condition Relapsed or refractory multiple myeloma after 1–3 prior lines of therapy, including an anti-CD38 antibody and lenalidomide More →
